[{"arm_notes": "", "treatment_id": null, "treatment_name": "ARM 4 - Severe COVID-19 infectionDrug: LenzilumabDose: 600mg 8 hourlyDuration: 24 hoursMode: Intravenous - administered by nurse.adherence: inpatient recordsDescription of study design:This SMART design specifies that participants entering the trial who have had no known COVID-19 exposure are initially randomised to either low-dose intranasal IFN-a or placebo as pre-exposure prophylaxis against developing COVID-19. Any participants who have a known COVID-19 exposure are randomised to high-dose IFN-a or placebo as a post-exposure prophylaxis against developing COVID-19. If; at any stage after enrolling; a participant develops \u2018moderate\u2019 COVID-19; then they are then randomised to either selinexor or placebo; and if at any stage after enrolling the participant develops \u2018severe\u2019 COVID-19 they are then randomised to either lenzilumab or placebo.Importantly; participants enrolling into the trial can directly enter any of the four interventions if they meet the appropriate entry criteria.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 726, "treatment_name": "Lenzilumab", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]